135 related articles for article (PubMed ID: 24200150)
1. Flecainide toxicity--treatment with intravenous fat emulsion and extra corporeal life support.
Sivalingam SK; Gadiraju VT; Hariharan MV; Atreya AR; Flack JE; Aziz H
Acute Card Care; 2013 Dec; 15(4):90-2. PubMed ID: 24200150
[No Abstract] [Full Text] [Related]
2. A life-threatening flecainide overdose treated with intravenous fat emulsion.
Ellsworth H; Stellpflug SJ; Cole JB; Dolan JA; Harris CR
Pacing Clin Electrophysiol; 2013 Mar; 36(3):e87-9. PubMed ID: 22882363
[TBL] [Abstract][Full Text] [Related]
3. Confused and Too Long: Neurotoxicity and Cardiac Toxicity of Flecainide.
Tsai TF; Garcia RT; Bui JQ; Thinda A; Amsterdam EA
Crit Pathw Cardiol; 2017 Mar; 16(1):42-45. PubMed ID: 28195943
[No Abstract] [Full Text] [Related]
4. Life-threatening flecainide overdose treated with intralipid and extracorporeal membrane oxygenation.
Brumfield E; Bernard KR; Kabrhel C
Am J Emerg Med; 2015 Dec; 33(12):1840.e3-5. PubMed ID: 25921969
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of flecainide-induced cardiac arrest with extracorporeal membrane oxygenation in the ED.
Reynolds JC; Judge BS
Am J Emerg Med; 2015 Oct; 33(10):1542.e1-2. PubMed ID: 26299692
[TBL] [Abstract][Full Text] [Related]
6. Use of intravenous lipid 20% emulsion for the treatment of a voluntary intoxication of flecainide with refractory shock.
Moussot PE; Marhar F; Minville V; Vallé B; Dehours E; Bounes V; Ducassé JL
Clin Toxicol (Phila); 2011 Jul; 49(6):514. PubMed ID: 21824065
[No Abstract] [Full Text] [Related]
7. Extracorporeal life support in a case of fatal flecainide and betaxolol poisoning allowing successful cardiac allograft.
Vivien B; Deye N; Mégarbane B; Marx JS; Leprince P; Bonnet N; Roussin F; Jacob L; Pavie A; Baud FJ; Carli P
Ann Emerg Med; 2010 Oct; 56(4):409-12. PubMed ID: 20172626
[TBL] [Abstract][Full Text] [Related]
8. [Paroxysmal atrial fibrillation: which patients need anti-arrhythmia drugs?. Interview by Dr. med. Ulrike Hennemann].
Meinertz T
Fortschr Med; 1996 Aug; 114(24):42-3. PubMed ID: 8974971
[No Abstract] [Full Text] [Related]
9. Analysis of heart rate variability in a patient with paroxysmal atrial fibrillation.
van den Berg MP; Haaksma J; Brouwer J; Crijns HJ; Lie KI
Eur Heart J; 1995 Dec; 16(12):2011-2. PubMed ID: 8682048
[No Abstract] [Full Text] [Related]
10. A new approach for treatment of refractory ventricular fibrillation allowed by extra corporeal life support (ECLS)?
Jouffroy R; Lamhaut L; Philippe P; An K; Carli P; Vivien B
Resuscitation; 2014 Aug; 85(8):e118. PubMed ID: 24810737
[No Abstract] [Full Text] [Related]
11. [The use of digitalis glycosides in atrial fibrillation].
Knez A; Haberl R; Steinbeck G
Z Kardiol; 1994; 83 Suppl 5():71-3. PubMed ID: 7846948
[TBL] [Abstract][Full Text] [Related]
12. [Life-threatening ventricular tachycardia during flecainide treatment for symptomatic atrial fibrillation in a patient with a structural cardiac disorder].
Rienstra M; Wiesfeld AC; van Veldhuisen DJ; van Gelder IC
Ned Tijdschr Geneeskd; 2006 May; 150(18):1027-31. PubMed ID: 16715868
[TBL] [Abstract][Full Text] [Related]
13. Flecainide toxicity in an older adult.
Psaty BM; Psaty SE
J Am Geriatr Soc; 2009 Apr; 57(4):751-3. PubMed ID: 19392975
[No Abstract] [Full Text] [Related]
14. [Intravenous flecainide administration for conversion of paroxysmal atrial fibrillation in the emergency room].
Antonelli D; Feldman A; Freedberg NA; Darawsha A; Rosenfeld T
Harefuah; 2006 May; 145(5):342-4, 398. PubMed ID: 16805213
[TBL] [Abstract][Full Text] [Related]
15. The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events.
Almroth H; Andersson T; Fengsrud E; Friberg L; Linde P; Rosenqvist M; Englund A
J Intern Med; 2011 Sep; 270(3):281-90. PubMed ID: 21635583
[TBL] [Abstract][Full Text] [Related]
16. Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone. A randomized, placebo-controlled study.
Cotter G; Blatt A; Kaluski E; Metzkor-Cotter E; Koren M; Litinski I; Simantov R; Moshkovitz Y; Zaidenstein R; Peleg E; Vered Z; Golik A
Eur Heart J; 1999 Dec; 20(24):1833-42. PubMed ID: 10581142
[TBL] [Abstract][Full Text] [Related]
17. Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide.
Taylor R; Gandhi MM; Lloyd G
BMJ; 2010 Mar; 340():b4684. PubMed ID: 20219811
[TBL] [Abstract][Full Text] [Related]
18. Some patients with paroxysmal atrial fibrillation should carry flecainide or propafenone to self treat.
Camm AJ; Savelieva I
BMJ; 2007 Mar; 334(7594):637. PubMed ID: 17379911
[No Abstract] [Full Text] [Related]
19. The effectiveness and timing of elective pharmacological cardioversion for paroxysmal atrial fibrillation.
Shah DC
Eur Heart J; 1999 Dec; 20(24):1768-9. PubMed ID: 10581132
[No Abstract] [Full Text] [Related]
20. Flecainide: Electrophysiological properties, clinical indications, and practical aspects.
Paolini E; Stronati G; Guerra F; Capucci A
Pharmacol Res; 2019 Oct; 148():104443. PubMed ID: 31493514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
